Injectable Therapy for Diabetes Mellitus: Glucagon-Like Peptide-1 Receptor Agonist.

Lee,  Inkuk; Kang,  Eun Seok

doi:2019.20.3.149

J Korean Diabetes > Volume 20(3); 2019 > Article

Focused Issue

The Journal of Korean Diabetes 2019;20(3):149-156.
DOI: https://doi.org/10.4093/jkd.2019.20.3.149 Published online October 2, 2019.

당뇨병 주사제: Glucagon-Like Peptide-1 수용체작용제

이인국, 강은석

Injectable Therapy for Diabetes Mellitus: Glucagon-Like Peptide-1 Receptor Agonist.

Inkuk Lee, Eun Seok Kang

¹Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. edgo@yuhs.ac
²Severance Hospital Diabetes Center, Seoul, Korea.
³Institute of Endocrine Research, Yonsei University College of Medicine, Seoul, Korea.

Abstract

According to the American Diabetes Association (ADA) and the European Association for the Study of Diabetes guideline for treatment of diabetes, glucagon-like peptide-1 receptor agonist (GLP-1 RA) is recommended in diabetic patients with established atherosclerotic cardiovascular disease. This recommendation is based on the results of recent cardiovascular outcome trials of this kind of medications. GLP-1 RAs have a glucose lowering effect with weight loss and a lower incidence of hypoglycemia, and can improve cardiovascular outcomes such as three-point major cardiovascular events composed of death from cardiovascular causes, non-fatal myocardial infarction, and non-fatal stroke. Also, several GLP-1 RAs have beneficial effects on renal outcomes, mainly due to improvement in macroalbuminuria. In addition, high-dose liraglutide (3 mg/day subcutaneous injection) showed efficacy for reducing body weight. Therefore GLP-1 RA may be effective in patients with established cardiovascular disease, chronic kidney disease, and/or metabolic syndrome.

Key Words: Cardiovascular diseases, Diabetes mellitus, Glucagon-like peptide-1, Kidney diseases, Obesity